Huaren Pharmaceutical

What Huaren Pharmaceutical does

Huaren Pharmaceutical Co., Ltd. (华仁药业股份有限公司, stock code: 300110) is a state-controlled pharmaceutical manufacturer founded in 1998 in Qingdao, Shandong Province, and listed on the Shenzhen Stock Exchange since August 2010. Since July 2019, the company's actual controller has been the Xi'an Qujiang New Area Management Committee. The company operates a vertically integrated portfolio across four core pharmaceutical segments: large-volume parenterals (sodium chloride, glucose, compound electrolytes, lactate Ringer's — 69 types and 143 specifications, designated as a Shandong provincial emergency reserve infusion producer); peritoneal dialysis solutions (China's first non-PVC packaged product, holding the #1 domestic market share with 23 approved specifications); therapeutic infusions spanning cardiovascular, anti-infective, respiratory, and anesthesia categories; and APIs plus pharmaceutical packaging materials including halobutyl rubber stoppers, synthetic polyisoprene stoppers, and non-PVC co-extruded films. Manufacturing is supported by six production bases with combined annual capacity of 950 million bags/bottles, BFS (Blow-Fill-Seal) integrated process technology, GMP-compliant systems with internal standards exceeding Chinese Pharmacopoeia requirements, and Italy Stilmas water treatment plus German PLUMAT filling equipment.

The company's go-to-market is sales-led via a national direct sales force targeting hospitals and clinics, supplemented by participation in government centralized volume-based procurement programs (Beijing-Tianjin-Hebei '3+N' alliance, Shandong, Zhejiang, Guangdong), a specialized home delivery service for peritoneal dialysis patients covering all 11 prefecture-level cities in Zhejiang, and retail distribution for its growing 'Great Health' consumer product line (electrolyte drinks, medical skincare, pharmaceutical-grade purified water). Revenue is generated primarily through one-time sales of prescription pharmaceuticals, medical devices, APIs, and packaging materials to medical institutions, with pricing materially influenced by centralized procurement (peritoneal dialysis products absorbed over 50% price reductions to win Zhejiang tender in 2025). The company holds 570+ authorized patents including a national invention patent for Icodextrin technology, and maintains industry-academia partnerships with Tongji University and the National Ministry of Health Hospital Management Research Institute.

The business model reflects a hybrid of legacy large-volume infusion manufacturing and differentiated specialty franchises (non-PVC peritoneal dialysis, hemofiltration replacement fluids). Recent strategic actions include a December 2025 framework agreement with Feidong County Government for an API production base to advance vertical backward integration, October 2025 wins in the Beijing-Tianjin-Hebei '3+N' centralized procurement, and ongoing product registration activity (Nefopam Hydrochloride Injection, Sodium Lactate Ringer's 1000ml consistency evaluation). Customer concentration is split between institutional hospital procurement and individual chronic kidney disease patients receiving home delivery, with the company explicitly serving as a Shandong provincial emergency reserve producer for infusions.

Name

Huaren Pharmaceutical

Legal name

华仁药业股份有限公司

Website

https://qdhuaren.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Huaren Pharmaceutical is a state-controlled Chinese pharmaceutical manufacturer (Shenzhen-listed, 300110) producing large-volume infusions, peritoneal dialysis solutions, therapeutic drugs, APIs, and medical devices for hospitals and chronic kidney disease patients across China, with six production bases and 950 million bags/bottles annual capacity.

Ownership category

akta.pro rank

Product category

Sterile Infusion and Peritoneal Dialysis Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Peritoneal Dialysis (PD) Systems & Supplies (HLAHAKAB), Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA), Pharmaceutical & Medical Device Packaging (GMP, Tamper-Evident, Cold-Chain Packs) (TLAIAGAI)

Keywords

• Sterile infusion manufacturing
• Peritoneal dialysis solutions
• Large-volume parenterals
• Pharmaceutical packaging materials
• Active pharmaceutical ingredients

Headquarters

HQ city

Qingdao Shi

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription pharmaceutical products including infusion solutions, peritoneal dialysis liquids, therapeutic输液, respiratory medications, anesthesia drugs, and medical devices to hospitals, clinics, and medical institutions through direct sales and tendering processes.
2. Medical Device Sales: Sale of medical devices including masks, protective equipment, surgical instruments, and dialysis accessories to healthcare institutions.
3. Pharmaceutical Packaging Materials: Sale of pharmaceutical packaging products including rubber stoppers, film materials, and carton packaging to pharmaceutical manufacturers.
4. Active Pharmaceutical Ingredients (API): Sale of active pharmaceutical ingredients including hydroxyethyl starch, doxofylline, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and lec卡地平盐酸盐.
5. Great Health Consumer Products: Sale of consumer health products including electrolyte drinks, skincare products, and purified drinking water to end consumers.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Huaren Pharmaceutical is a vertically integrated pharmaceutical manufacturer that produces and sells sterile infusion solutions, peritoneal dialysis liquids, therapeutic injections, active pharmaceutical ingredients (APIs), medical devices, and pharmaceutical packaging materials. Its flagship offering is China's first non-PVC packaged peritoneal dialysis solution, which holds the #1 domestic market share. The company operates six production bases with a combined annual capacity of 950 million bags/bottles and supports a nationwide network of hospital sales, government centralized procurement, and direct patient delivery services.

Product overview

Huaren Pharmaceutical (华仁药业股份有限公司, stock code 300110) is a state-controlled pharmaceutical manufacturing group established in 1998 and listed on the Shenzhen Stock Exchange in 2010. The company operates a vertically integrated portfolio organized around four core segments: (1) 基础性输液/大容量制剂 (basic/large-volume infusions) — including sodium chloride, glucose, compound electrolytes, lactate Ringer's, and sterile water; (2) 腹膜透析液 (peritoneal dialysis solutions) — the company's landmark product line, China's first non-PVC packaged peritoneal dialysis fluid, commanding the #1 market share domestically, with 23 approved specifications across standard and low-calcium variants, plus 血液滤过置换液 (hemofiltration replacement fluids); (3) 治疗性输液/呼吸科/精麻科产品 (therapeutic infusions) — including blood volume expanders (羟乙基淀粉130), cardiovascular drugs, anti-infectives, hepatoprotectants, anti-tumor adjuvants, bronchodilators (多索茶碱), antibiotics (左氧氟沙星), anesthetics (枸橼酸咖啡因); and (4) 医药包装/原料药 (pharmaceutical packaging and APIs) — including halobutyl rubber stoppers, synthetic polyisoprene stoppers, non-PVC co-extruded films, and APIs such as hydroxyethyl starch, doxofylline, and potassium salts. The company also operates a growing 大健康 (big health) consumer division covering medical skincare products (名济堂/仁之净 series), functional beverages (久源久 electrolyte drinks), and purified drinking water. Manufacturing is supported by six production bases with total capacity of 950 million bags/bottles per year, BFS blow-fill-seal technology, and GMP-compliant quality systems with internal standards exceeding 《中国药典》 requirements.

Differentiator

Problem solved

Functional benefit

Products and services

• Peritoneal Dialysis Solution (Lactate-based) (腹膜透析液) China's first domestically mass-produced non-PVC packaged peritoneal dialysis liquid for chronic renal failure patients, eliminating plasticizer contamination risk. Covers multiple specifications from 1000ml to 3000ml. Holds the #1 market share in China's non-PVC peritoneal dialysis liquid market. Used by nephrology departments and home dialysis patients.
• Large-Volume Parenterals / Basic Infusions (大容量制剂) Comprehensive basic infusion portfolio including 0.9% Sodium Chloride Injection, Glucose Injection, Glucose Sodium Chloride Injection, Compound Sodium Chloride Injection, Compound Electrolyte Injection, Lactate Ringer's Injection, and Sterile Water for Injection. Includes 69 pharmaceutical types and 143 specifications total. Designated as Shandong Province emergency reserve infusion production enterprise. Both 500ml and 1000ml specifications of Lactate Ringer's Injection have passed generic drug consistency evaluation (2026).
• Low-Calcium Peritoneal Dialysis Solution (低钙腹膜透析液) Peritoneal dialysis solution formulated for patients requiring calcium-phosphate binder regimens including hypercalcemia patients, hyperphosphatemia patients, and those with elevated parathyroid hormone. Available in concentrations of 1.5%, 2.5%, and 4.25%, with 1000ml and 2000ml specifications.
• Hemofiltration Replacement Fluids (血液滤过置换液) Dedicated replacement solution for hemofiltration therapy to replace water and electrolytes in the body, partially substituting kidney function. Available in 1000ml and 2000ml specifications, used in blood purification treatment for critically ill renal patients.
• Hydroxyethyl Starch 130 Sodium Chloride Injection (羟乙基淀粉130氯化钠注射液) Blood volume expander for treatment and prevention of hypovolemia and acute normovolemic hemodilution (ANH). Available in 250ml and 500ml specifications and listed in the 2018 National Essential Medicines List as the only selected blood volume expander.
• Doxofylline Injection (多索茶碱注射液) Bronchodilator for bronchial asthma, chronic asthmatic bronchitis, and other bronchospasm-induced breathing difficulties. Available in 10ml:0.1g, 10ml:0.2g, and 20ml:0.3g specifications. Used in respiratory departments of hospitals.
• Levofloxacin Hydrochloride Injection (盐酸左氧氟沙星注射液) Anti-infective for hospital-acquired pneumonia, community-acquired pneumonia, and acute bacterial sinusitis. Available in 5ml:0.5g and 5ml:0.25g specifications. Used across multiple hospital departments.
• Sodium Citrate Caffeine Injection (枸橼酸咖啡因注射液) Anesthetic used for treatment of primary apnea in premature newborns. Available in 3ml:60mg specification. Sold as a controlled substance through dedicated精麻科 (anesthesia) sales channel.
• Nefopam Hydrochloride Injection (盐酸奈福泮注射液) Pain management injection obtained by wholly-owned subsidiary in October 2025, expanding the company's精麻科 (anesthesia) product portfolio.
• Disposable Medical Masks (一次性使用医用口罩) Three-layer protective masks composed of non-woven fabric, melt-blown filter fabric, nose bridge strip, and mask straps. Certified by China National Medical Products Administration, listed in the China Medical Health Products Import and Export Chamber of Commerce whitelist, and EU CE certified.
• Disposable Medical Protective Suits (医用一次性防护服) Full-body protective suits made from film-coated non-woven fabric, providing barrier protection for clinical medical staff when in contact with potentially infectious patients' blood, body fluids, and secretions. Sterile, single-use. Subsidiary obtained medical device registration certificate in July 2020.
• Disposable Trocar/Puncture Sets (一次性套管穿刺器) Used in laparoscopic surgery as channels for endoscopes and surgical instruments to enter the body. Features dual-wall sealed structure with proprietary domestic wiping device design. Applicable for hepatobiliary surgery, gastrointestinal surgery, urological surgery, and gynecology.
• Disposable Peritoneal Dialysis Drainage Bags (一次性使用腹透引流袋) PVC drainage bags used in conjunction with peritoneal dialysis solution for collecting waste fluid from peritoneal dialysis patients. Available in 2000ml, 3500ml, and 4000ml specifications. Sold alongside peritoneal dialysis products for home dialysis patient use.
• Active Pharmaceutical Ingredients (APIs) (原料药系列) API portfolio including Hydroxyethyl Starch 130, Doxofylline, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and Lecadipine hydrochloride salt. APIs are used in Huaren's own formulation production and sold to other pharmaceutical manufacturers. New API production base project signed with Feidong County Government on December 10, 2025.
• Halobutyl Rubber Stoppers for Injection (注射用冷冻干燥用溴化丁基橡胶塞) First domestically registered rubber stopper for lyophilized drug formulation packaging. Offers excellent chemical inertness and low-temperature sealing performance. Used for packaging cephalosporins, ceftazidime sodium, and various other drug formulations. Sold to pharmaceutical manufacturers.
• Non-PVC Three-Layer Co-extrusion Infusion Film (非PVC三层共挤输液用膜) Three-layer (PP/SEBS/PP) co-extruded film for infusion bags. Eliminates plasticizer concerns and prevents drug component migration and adsorption. High barrier properties against water vapor, oxygen, and nitrogen. Used for various capacity injection packaging.
• Jiuyuanjiu Glucose Electrolyte Drinks (久源久葡萄糖补水液) Glucose energy beverages for quickly correcting discomfort caused by energy deficiency. Available in four flavors: peach, lemon, lychee, and original. 450ML/bottle, 24 bottles/case. Distributed through retail pharmacy and consumer channels.
• Renzhi Jing Purified Drinking Water (仁之净饮用纯净水) Bottled and barreled purified drinking water derived from Huaren's pharmaceutical infusion-grade water treatment technology. Suitable for daily cooking, elderly medication, and direct infant formula preparation. 450mL/bottle, 24 bottles/case.
• Mingjitang Vitamin E Moisturizing Cream (名济堂维生素E水润霜) Pharmaceutical-grade skincare cream containing natural rice bran oil (no mineral oil) and herbal extracts including gentian root and licorice. Features high-concentration Vitamin E anti-oxidation benefits. Designed for dry and sensitive skin. Net content 50g.
• Icodextrin Medical Cold Compress Mask (艾考糊精医用冷敷贴) First-class medical device developed using Huaren's national invention patent and Class 3 new drug Icodextrin API platform. Used for auxiliary reduction of redness and swelling after sprains and contusions, post-sunburn dermatitis, and acne-related skin repair. Sold through retail and pharmacy channels.

Quantifiable outcome

• Non-PVC peritoneal dialysis liquid market share ranked first in China
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• 肥东县人民政府 (Feidong County Government)flagshipStrategic or Co-development Partner · 10 December 2025On December 10, 2025, Huaren Pharmaceutical formally signed a cooperation framework agreement with Feidong County Government for the API (active pharmaceutical ingredient) production base project. This strategic project marks the company's 'original medicine' strategy (原...战略) advancement and will serve as a key production base for pharmaceutical raw materials.
• 国家卫生部医院管理研究所 (National Ministry of Health Hospital Management Research Institute)coreStrategic or Co-development Partner · 17 June 2011Huaren Pharmaceutical and the National Ministry of Health Hospital Management Research Institute jointly launched the 'National Ministry of Health Peritoneal Dialysis Training, Demonstration and Promotion Project' (国家卫生部腹膜透析培训、示范及推广项目) on June 17, 2011. This collaboration established national training standards for peritoneal dialysis treatment and promoted the application of non-PVC packaged peritoneal dialysis solutions.
• 同济大学 (Tongji University)coreStrategic or Co-development PartnerHuaren Pharmaceutical maintains deep industry-academia-research (产学研) cooperation with Tongji University. The collaboration focuses on translating innovative research outcomes and orderly layout of the great health business segment, supporting the company's medium-to-long-term transformation and development.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• China Resources Double-Crane Pharmaceutical: Major Chinese pharmaceutical manufacturer with a strong infusion business and therapeutic injectables. Competes head-to-head with Huaren in hospital tendering and centralized procurement for large-volume parenterals.
• Sichuan Kelun Pharmaceutical: Largest Chinese large-volume parenteral infusion manufacturer with a broad infusion portfolio and PD solutions. Direct competitor to Huaren in Chinese hospital infusion channels and the same product families (Ringer's, glucose, sodium chloride).
• Joincare Pharmaceutical Group: Chinese pharmaceutical group with a meaningful portfolio in injectables, APIs, and respiratory drugs. Overlaps with Huaren in therapeutic infusion and active pharmaceutical ingredient categories.

Broad incumbents

• Terumo: Japanese medical devices and pharmaceutical company with a strong infusion systems and PD business in Asia. Comparable to Huaren in medical device and infusion manufacturing, particularly in Asia-Pacific markets.
• Baxter International: Global manufacturer of PD solutions (Dianeal, Extraneal) and large-volume parenterals. Competes with Huaren in PD and infusion categories, particularly in higher-tier Chinese hospitals.
• B. Braun: Global leader in infusion therapy and peritoneal dialysis solutions. Operates a China presence and competes with Huaren in PD solutions and clinical infusion products, particularly in higher-tier hospitals.
• Shanghai Pharmaceuticals Holding: One of China's largest state-controlled pharmaceutical groups with a broad infusion and injectable portfolio. Comparable to Huaren as a Chinese state-affiliated pharma player with overlapping therapy areas and centralized procurement exposure.
• Fresenius Medical Care: Global leader in dialysis products and services, including the dominant peritoneal dialysis franchise. Sets the global technology and quality benchmark that Huaren competes against in the Chinese PD market.

Regional players

• DaVita: Major US dialysis services and product company focused on hemodialysis and peritoneal dialysis. Demonstrates the patient-service and supply economics relevant to Huaren's PD home-delivery model, though geographically distinct.

Emerging players

• Hunan Er-Kang Pharmaceutical: Chinese pharmaceutical manufacturer specializing in pharmaceutical excipients, packaging materials, and APIs. Comparable to Huaren's pharmaceutical packaging and API business segments (rubber stoppers, films, APIs).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/huaren-pharmaceutial-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huaren Pharmaceutical